First-line chemotherapy for HER-2-negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment

Alessandro Morabito, Maria Carmela Piccirillo, Katia Monaco, Carmen Pacilio, Francesco Nuzzo, Paolo Chiodini, Ciro Gallo, Andrea De Matteis, Francesco Perrone

Research output: Contribution to journalArticle

Abstract

The treatment decision for patients with metastatic breast cancer who have received anthracyclines within the course of adjuvant chemotherapy is troublesome, particularly if trastuzumab and hormonal treatment are not indicated. In the first part of this review we discuss the value of retreatment with anthracyclines, a topic that has been indirectly evaluated by retrospective studies with conflicting results and within a small phase III trial with a negative outcome. Evidence on liposomal anthracyclines is also reviewed. In the second part of the review, alternative options of first-line chemotherapy are discussed. These include taxanes as single agents, taxanes in combination with other cytotoxic drugs, combinations without anthracyclines and taxanes, and innovative treatments including target-based agents. Both the amount and the quality of evidence on these treatments are poor. Few phase III studies are available and most of them have been performed with registrative aims sponsored by the companies who own the winning drug. Beyond indications derived from such studies, there is a great need for more clinical research in this setting.

Original languageEnglish
Pages (from-to)1288-1298
Number of pages11
JournalThe oncologist
Volume12
Issue number11
DOIs
Publication statusPublished - Nov 2007

Keywords

  • Adjuvant anthracyclines
  • First-line chemotherapy
  • Metastatic breast cancer
  • Taxanes

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Fingerprint Dive into the research topics of 'First-line chemotherapy for HER-2-negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment'. Together they form a unique fingerprint.

  • Cite this